BE2019C533I2 - - Google Patents

Info

Publication number
BE2019C533I2
BE2019C533I2 BE2019C533C BE2019C533C BE2019C533I2 BE 2019C533 I2 BE2019C533 I2 BE 2019C533I2 BE 2019C533 C BE2019C533 C BE 2019C533C BE 2019C533 C BE2019C533 C BE 2019C533C BE 2019C533 I2 BE2019C533 I2 BE 2019C533I2
Authority
BE
Belgium
Application number
BE2019C533C
Other languages
Dutch (nl)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BE2019C533I2 publication Critical patent/BE2019C533I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2019C533C 2005-05-25 2019-06-24 BE2019C533I2 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2006065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体

Publications (1)

Publication Number Publication Date
BE2019C533I2 true BE2019C533I2 (cg-RX-API-DMAC10.html) 2025-12-10

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C533C BE2019C533I2 (cg-RX-API-DMAC10.html) 2005-05-25 2019-06-24

Country Status (20)

Country Link
US (4) US8084460B2 (cg-RX-API-DMAC10.html)
EP (1) EP1889848B8 (cg-RX-API-DMAC10.html)
JP (1) JP4323547B2 (cg-RX-API-DMAC10.html)
KR (1) KR100912782B1 (cg-RX-API-DMAC10.html)
CN (1) CN101228172B (cg-RX-API-DMAC10.html)
AU (1) AU2006250390B2 (cg-RX-API-DMAC10.html)
BE (1) BE2019C533I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0610343B8 (cg-RX-API-DMAC10.html)
CA (1) CA2609733C (cg-RX-API-DMAC10.html)
DK (1) DK1889848T3 (cg-RX-API-DMAC10.html)
ES (1) ES2525215T3 (cg-RX-API-DMAC10.html)
FR (1) FR19C1042I2 (cg-RX-API-DMAC10.html)
HU (1) HUS1900034I1 (cg-RX-API-DMAC10.html)
MX (1) MX2007014588A (cg-RX-API-DMAC10.html)
NL (1) NL300996I2 (cg-RX-API-DMAC10.html)
PL (1) PL1889848T3 (cg-RX-API-DMAC10.html)
PT (1) PT1889848E (cg-RX-API-DMAC10.html)
RU (1) RU2403255C2 (cg-RX-API-DMAC10.html)
TW (1) TWI311056B (cg-RX-API-DMAC10.html)
WO (2) WO2006126529A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ[2.2.2]オクタンを有するモルヒナン誘導体およびその医薬用途
MX347741B (es) * 2008-09-16 2017-05-10 Nektar Therapeutics Opioides pegilados con bajo potencial de abuso.
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
CN102906099A (zh) * 2010-05-13 2013-01-30 株式会社绿十字 作为神经保护剂的基于(+)-3-羟基吗啡喃的多环衍生物
WO2012063933A1 (ja) * 2010-11-12 2012-05-18 塩野義製薬株式会社 6,7-不飽和-7-カルバモイルモルヒナン誘導体の結晶およびその製造方法
PL2851075T3 (pl) 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
EP3560487A4 (en) * 2016-12-26 2020-07-29 Shionogi & Co., Ltd. PRODUCTION METHOD FOR FORMULATION WITH IMPROVED UNIFORMITY OF CONTENT
TW202528300A (zh) 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
ES3035561T3 (en) 2019-10-16 2025-09-04 Morphic Therapeutic Inc Inhibiting human integrin alpha4beta7
EP4062973A4 (en) 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) * 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
CA2143864C (en) 1993-07-23 2006-01-24 Hiroshi Nagase Morphinan derivatives and pharmaceutical use thereof
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
WO1997025331A1 (en) 1996-01-10 1997-07-17 Smithkline Beecham S.P.A. Heterocycle-condensed morphinoid derivatives (ii)
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
MXPA02005335A (es) 1999-11-29 2003-01-28 Adolor Corp Metodos y composiciones novedosos que incluyen opioides y antagonistas de los mismos.
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
EP1280529A2 (en) 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
WO2002036573A2 (en) * 2000-10-31 2002-05-10 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AU2408602A (en) * 2000-11-22 2002-06-03 Toray Industries Indole derivatives and use thereof in medicines
DE60236171D1 (de) * 2001-08-23 2010-06-10 Organon Nv Verfahren for zur herstellung eines 14-hydroxynormorphinon-derivats
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
AU2003281042A1 (en) 2002-07-11 2004-02-02 Toray Industries, Inc. Therapeutic or preventive agent for nausea/vomiting
AU2003299045A1 (en) 2002-09-18 2004-04-08 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
CA2568249C (en) 2004-05-28 2014-12-09 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
WO2012063933A1 (ja) 2010-11-12 2012-05-18 塩野義製薬株式会社 6,7-不飽和-7-カルバモイルモルヒナン誘導体の結晶およびその製造方法

Also Published As

Publication number Publication date
WO2006126529A1 (ja) 2006-11-30
NL300996I2 (nl) 2019-07-30
KR100912782B1 (ko) 2009-08-18
TW200726470A (en) 2007-07-16
NL300996I1 (nl) 2019-07-03
BRPI0610343B8 (pt) 2021-05-25
US8536192B2 (en) 2013-09-17
DK1889848T3 (en) 2014-12-01
CN101228172B (zh) 2013-04-03
RU2007148412A (ru) 2009-06-27
PL1889848T3 (pl) 2015-04-30
US8084460B2 (en) 2011-12-27
BRPI0610343A2 (pt) 2010-06-15
BRPI0610343B1 (pt) 2020-03-10
TWI311056B (en) 2009-06-21
USRE46375E1 (en) 2017-04-25
US20090203723A1 (en) 2009-08-13
CA2609733C (en) 2011-07-19
WO2006126637A1 (ja) 2006-11-30
EP1889848B1 (en) 2014-10-15
JP4323547B2 (ja) 2009-09-02
AU2006250390A1 (en) 2006-11-30
MX2007014588A (es) 2008-01-24
CA2609733A1 (en) 2006-11-30
ES2525215T3 (es) 2014-12-19
USRE46365E1 (en) 2017-04-11
RU2403255C2 (ru) 2010-11-10
US20120135978A1 (en) 2012-05-31
CN101228172A (zh) 2008-07-23
PT1889848E (pt) 2014-12-09
FR19C1042I2 (fr) 2020-06-19
EP1889848B8 (en) 2014-12-17
HUS1900034I1 (hu) 2019-07-29
EP1889848A1 (en) 2008-02-20
JPWO2006126637A1 (ja) 2008-12-25
FR19C1042I1 (cg-RX-API-DMAC10.html) 2019-08-09
AU2006250390B2 (en) 2010-07-08
KR20080014791A (ko) 2008-02-14
EP1889848A4 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
BE2023C529I2 (cg-RX-API-DMAC10.html)
BE2021C524I2 (cg-RX-API-DMAC10.html)
BE2021C519I2 (cg-RX-API-DMAC10.html)
BE2020C531I2 (cg-RX-API-DMAC10.html)
BE2020C511I2 (cg-RX-API-DMAC10.html)
BE2020C508I2 (cg-RX-API-DMAC10.html)
BE2020C004I2 (cg-RX-API-DMAC10.html)
BE2019C521I2 (cg-RX-API-DMAC10.html)
BE2019C503I2 (cg-RX-API-DMAC10.html)
BE2018C037I2 (cg-RX-API-DMAC10.html)
BE2018C035I2 (cg-RX-API-DMAC10.html)
BE2018C016I2 (cg-RX-API-DMAC10.html)
BE2017C028I2 (cg-RX-API-DMAC10.html)
BE2018C028I2 (cg-RX-API-DMAC10.html)
BE2019C533I2 (cg-RX-API-DMAC10.html)
BE2015C074I2 (cg-RX-API-DMAC10.html)
BE2014C057I2 (cg-RX-API-DMAC10.html)
BE2013C074I2 (cg-RX-API-DMAC10.html)
BE2013C014I2 (cg-RX-API-DMAC10.html)
BE2012C042I2 (cg-RX-API-DMAC10.html)
BE2012C028I2 (cg-RX-API-DMAC10.html)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004707A2 (cg-RX-API-DMAC10.html)
BRPI0609157A8 (cg-RX-API-DMAC10.html)